Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy

#1155

Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.

Aim(s): Our objective was to evaluate the clinical characteristics of PRRT patients who developed secondary hematologic malignancies (HM) as a long-term toxicity.

Materials and methods: Patients (pts) eligible for evaluation received PRRT for unresectable NETs between April 1997 - December 2010. Parameters including age, gender, time interval from diagnosis to hematologic malignancy, total cumulative radiolabel dose (GBq), and treatments were analyzed by descriptive statistics. Comparative analysis was performed using t- and z-tests.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Richter S

Authors: Richter S, Xenocostas A, Sanatani M, Davidson R, Novak K,

Keywords: PRRT,